source
- Capricor Therapeutics sees stock surge as FDA signals openness to extend review of DMD cell therapyCapricor Therapeutics' CEO Linda Marbán told investors that the FDA is receptive to adding open label extension data to its Biologics License Application for deramiocel, its Duchenne muscular dystr…
- Capricor to submit additional data to FDA after negative advisory committee vote on Duchenne therapyCapricor Therapeutics announced it will request the FDA to review new data and analyses for its experimental treatment for Duchenne muscular dystrophy. The move follows a recent negative vote from…